Cure My Disease

Don't miss your cure!

 Log in / Sign up

App aims to boost medication adherence in blood cancer patients

NCT ID NCT06713811

Disease control Sponsor: Private Hospital of Confluent, France Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This trial tests whether a telemonitoring app called Cureety helps blood cancer patients take their oral therapies correctly and manage side effects. Participants will either use the app to report symptoms and track adherence or receive standard follow-up care. The goal is to see if the app improves medication compliance and reduces complications.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Cureety telemonitoring platform
What this could lead to
If effective, this app could help blood cancer patients take their oral medications correctly and catch side effects early, improving treatment outcomes and quality of life.
What could go wrong
This is a single-center study with 110 participants, so results may not apply broadly. The app's benefit over standard care is unproven, and technical issues or patient reluctance could limit its use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 110 people

The number the study aims to enrol. It can still change while the study runs.

Started

May 2025

Expected to finish

Jul 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Follow-up for haemopathy justifying initiation of oral therapy (one or more authorized molecules) for more than 6 months (1st line of treatment or more), * Intravenous treatment may be associated with it, in accordance with international recommendations (immunotherapy, corticosteroid therapy, other), * Patient affiliated to a social security scheme, * Patient having given written consent prior to any specific study procedure. Exclusion Criteria: * Oral treatment expected to last \< 6 months, * Cerebral tumor involvement, * Other active cancer \< 3 years, excluding skin, prostate and cervical carcinomas treated by surgery alone, * Pregnancy or breast-feeding * Persons deprived of their liberty, under guardianship or curatorship, * Dementia, mental alteration or psychiatric pathology that could compromise the patient's informed consent and/or compliance with the protocol and trial follow-up, * Patient unable to undergo protocol monitoring for psychological, social, family or geographical reasons. * No Internet connection * No telephone line

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hemopathies are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematologic disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hemopathies

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    3 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Clinique de l'Europe

    RECRUITING

    Amiens, 80090, France

  • Clinique de la Baie

    RECRUITING

    Morlaix, 29672, France

  • Hôpital Privé du Confluent

    RECRUITING

    Nantes, 44000, France